328 related articles for article (PubMed ID: 20696525)
21. Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes.
Vera G; López-Miranda V; Herradón E; Martín MI; Abalo R
Pharmacol Biochem Behav; 2012 Aug; 102(2):335-43. PubMed ID: 22609797
[TBL] [Abstract][Full Text] [Related]
22. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
Deng L; Cornett BL; Mackie K; Hohmann AG
Mol Pharmacol; 2015 Jul; 88(1):64-74. PubMed ID: 25904556
[TBL] [Abstract][Full Text] [Related]
23. Cannabinoid 1 and mu-Opioid Receptor Agonists Synergistically Inhibit Abdominal Pain and Lack Side Effects in Mice.
Yu Y; Tsang QK; Jaramillo-Polanco J; Lomax AE; Vanner SJ; Reed DE
J Neurosci; 2022 Aug; 42(33):6313-6324. PubMed ID: 35790401
[TBL] [Abstract][Full Text] [Related]
24. Analgesic effects of cannabinoid receptor agonist WIN55,212-2 in the nucleus cuneiformis in animal models of acute and inflammatory pain in rats.
Ebrahimzadeh M; Haghparast A
Brain Res; 2011 Oct; 1420():19-28. PubMed ID: 21911208
[TBL] [Abstract][Full Text] [Related]
25. Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex.
Bambico FR; Katz N; Debonnel G; Gobbi G
J Neurosci; 2007 Oct; 27(43):11700-11. PubMed ID: 17959812
[TBL] [Abstract][Full Text] [Related]
26. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
Sain NM; Liang A; Kane SA; Urban MO
Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
[TBL] [Abstract][Full Text] [Related]
27. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.
de Lago E; Moreno-Martet M; Cabranes A; Ramos JA; Fernández-Ruiz J
Neuropharmacology; 2012 Jun; 62(7):2299-308. PubMed ID: 22342378
[TBL] [Abstract][Full Text] [Related]
28. Functional CB2 type cannabinoid receptors at CNS synapses.
Morgan NH; Stanford IM; Woodhall GL
Neuropharmacology; 2009 Sep; 57(4):356-68. PubMed ID: 19616018
[TBL] [Abstract][Full Text] [Related]
29. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway.
Fakhfouri G; Ahmadiani A; Rahimian R; Grolla AA; Moradi F; Haeri A
Neuropharmacology; 2012 Sep; 63(4):653-66. PubMed ID: 22634229
[TBL] [Abstract][Full Text] [Related]
30. Cannabinoids and Pain: Sites and Mechanisms of Action.
Starowicz K; Finn DP
Adv Pharmacol; 2017; 80():437-475. PubMed ID: 28826543
[TBL] [Abstract][Full Text] [Related]
31. WIN 55,212-2 Reverted Pilocarpine-Induced Status Epilepticus Early Changes of the Interaction among 5-HT
Di Maio R; Colangeli R; Di Giovanni G
ACS Chem Neurosci; 2019 Jul; 10(7):3296-3306. PubMed ID: 30912644
[TBL] [Abstract][Full Text] [Related]
32. Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.
Slivicki RA; Xu Z; Kulkarni PM; Pertwee RG; Mackie K; Thakur GA; Hohmann AG
Biol Psychiatry; 2018 Nov; 84(10):722-733. PubMed ID: 28823711
[TBL] [Abstract][Full Text] [Related]
33. Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain.
Nirogi R; Jabaris SL; Jayarajan P; Abraham R; Shanmuganathan D; Rasheed MA; Royapalley PK; Goura V
Eur J Pharmacol; 2011 Oct; 668(1-2):155-62. PubMed ID: 21756895
[TBL] [Abstract][Full Text] [Related]
34. The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain.
Liang YC; Huang CC; Hsu KS
Neuropharmacology; 2007 Jul; 53(1):169-77. PubMed ID: 17572451
[TBL] [Abstract][Full Text] [Related]
35. Cannabinoid subtype-2 receptors modulate the antihyperalgesic effect of WIN 55,212-2 in rats with neuropathic spinal cord injury pain.
Ahmed MM; Rajpal S; Sweeney C; Gerovac TA; Allcock B; McChesney S; Patel AU; Tilghman JI; Miranpuri GS; Resnick DK
Spine J; 2010 Dec; 10(12):1049-54. PubMed ID: 20920894
[TBL] [Abstract][Full Text] [Related]
36. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.
Rahn EJ; Makriyannis A; Hohmann AG
Br J Pharmacol; 2007 Nov; 152(5):765-77. PubMed ID: 17572696
[TBL] [Abstract][Full Text] [Related]
37. Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain.
Elmes SJ; Jhaveri MD; Smart D; Kendall DA; Chapman V
Eur J Neurosci; 2004 Nov; 20(9):2311-20. PubMed ID: 15525273
[TBL] [Abstract][Full Text] [Related]
38. Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation.
Mulpuri Y; Marty VN; Munier JJ; Mackie K; Schmidt BL; Seltzman HH; Spigelman I
Neuropharmacology; 2018 Sep; 139():85-97. PubMed ID: 29981335
[TBL] [Abstract][Full Text] [Related]
39. Effects of gonadal hormones on the peripheral cannabinoid receptor 1 (CB1R) system under a myositis condition in rats.
Niu KY; Zhang Y; Ro JY
Pain; 2012 Nov; 153(11):2283-2291. PubMed ID: 22940464
[TBL] [Abstract][Full Text] [Related]
40. CB1 receptors mediate the analgesic effects of cannabinoids on colorectal distension-induced visceral pain in rodents.
Brusberg M; Arvidsson S; Kang D; Larsson H; Lindström E; Martinez V
J Neurosci; 2009 Feb; 29(5):1554-64. PubMed ID: 19193902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
